$PRXL (PAREXEL International Corporation)

$PRXL {{ '2016-01-21T16:17:19+0000' | timeago}} • Announcement

Optum, part of $UNH, and $PRXL said that they have entered into a strategic alliance to reduce drug development costs associated with post-approval studies. The deal combines the strength of Optum's clinical data set derived from electronic health records (EHRs), claims data assets and analytics with $PRXL's global, site-based research experience.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$NLSN {{ '2017-07-20T18:54:03+0000' | timeago}} • Announcement

$NLSN declared a quarterly cash dividend of $0.34 per share of common stock. The dividend is payable on September 7, 2017 to stockholders of record at the close of business on August 24, 2017.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$TBPH {{ '2017-07-20T12:32:48+0000' | timeago}} • Announcement

$TBPH and $MYL announced positive results from a 12-month Phase 3 safety study of revefenacin in patients with chronic obstructive pulmonary disease (COPD). The study of 1,055 patients with COPD demonstrated that revefenacin was generally well-tolerated, and no new safety issues were identified.

$MSFT {{ '2017-07-19T21:56:12+0000' | timeago}} • Announcement

$MSFT and $DNB announces a strategic partnership. $DNB will use Microsoft Azure as its cloud platform. Dun & Bradstreet data will be made available through Microsoft Dynamics 365, a cloud-powered service, and the Microsoft’s Common Data Service. Also, the tech giant and D&B will enter into a co-selling arrangement beginning later this year.

$AKRX {{ '2017-07-19T21:41:28+0000' | timeago}} • Announcement

Specialty generic pharmaceutical company $AKRX said that its shareholders have voted to approve the merger for the acquisition of Akorn by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA. The companies expect the acquisition to close by early 2018.

$IBM {{ '2017-07-19T19:00:41+0000' | timeago}} • Webcast

$IBM expects improved revenue and gross margin performance in 2H17, pushed by its new IBM z systems mainframe servers launch in 2Q17. However, the company expects most of the growth to happen in 4Q17.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$DNB {{ '2017-07-19T14:40:03+0000' | timeago}} • Announcement

$DNB said it is teaming up with $MSFT to give companies worldwide direct access to its data through $MSFT's cloud services. $DNB has selected $MSFT as a strategic cloud provider to accelerate the company's digital transformation and deliver its customers more efficient and seamless access to its commercial data.

$IBM {{ '2017-07-18T23:42:39+0000' | timeago}} • Announcement

$IBM maintained its FY17 EPS and cash flow expectations. The company continues to expect adjusted diluted EPS of at least $13.80 and GAAP diluted EPS of at least $11.95. Free cash flow is expected to be relatively flat year-to-year.

$IBM {{ '2017-07-18T23:35:37+0000' | timeago}} • Announcement

Big Blue $IBM reported 21st consecutive quarter of revenue decline, with 2Q17 earnings declining 7%. The decline was driven by all segments reporting a decline in revenue YoY. Net income was $2.3Bil or $2.48 per share in 2Q17, down from $2.5Bil or $2.61 per share a year ago. Revenue declined 4.7% to $19.3Bil.

$IBM {{ '2017-07-18T21:07:52+0000' | timeago}} • Infographic

$IBM International Business Machines Earnings AlphaGraphic: Q2 2017 Highlights

$LH {{ '2017-07-18T13:30:08+0000' | timeago}} • Announcement

Insurance company $LH said its CEO William Hanlon has been appointed as a member of the governing committee of the National Evaluation System for Health Technology Coordinating Center. Hanlon has been focused on early and late-stage clinical development, as a regulatory affairs expert, for the past several years.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$MYL {{ '2017-07-14T12:05:52+0000' | timeago}} • Announcement

Pharma firm $MYL said the FDA Oncologic Drugs Advisory Committee has recommended approval of the biosimilar trastuzumab developed by Mylan along with India-based Biocon Ltd. for  treatment of breast cancer. The committee determined no clinically meaningful differences exist between the biosimilar product and cancer drug Herceptin.

Recent Transcripts

IBM (International Business Machines Corporation)
Tuesday, July 18 2017 - 9:00pm
INFY (Infosys Limited)
Friday, July 14 2017 - 12:30pm
INFY (Infosys Limited)
Friday, July 14 2017 - 6:00am
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
XON (Intrexon Corporation)
Wednesday, May 10 2017 - 8:30pm
MYL (Mylan N.V.)
Wednesday, May 10 2017 - 2:00pm
CRL (Charles River Laboratories International, Inc.)
Wednesday, May 10 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
CTSH (Cognizant Technology Solutions Corporation)
Friday, May 5 2017 - 12:00pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
PRXL (PAREXEL International Corporation)
Thursday, May 4 2017 - 2:00pm
Q (Quintiles Transnational Holdings Inc.)
Wednesday, May 3 2017 - 1:00pm
DNB (Dun & Bradstreet Corp.)
Tuesday, May 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
SNMX (Senomyx Inc.)
Thursday, April 27 2017 - 9:00pm
CERN (Cerner Corporation)
Thursday, April 27 2017 - 8:30pm
EXAS (Exact Sciences Corporation)
Thursday, April 27 2017 - 2:00pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
ICLR (ICON Public Limited Company)
Thursday, April 27 2017 - 1:00pm

AlphaGraphics you may like